The University of California, Berkeley Partners with NTT to Accelerate Smart Technologies
19.5.2020 01:00:00 EEST | Business Wire | Press release
The University of California, Berkeley and NTT Corporation (NTT) today announced a connected campus pilot project that will leverage technology to transform the UC Berkeley Parking and Transportation Department by analyzing patterns, easing traffic congestion and increasing pedestrian safety in the Bancroft Way area of campus.
The pilot will incorporate NTT’s Accelerate Smart data platform and Dell Technologies’ modular data center infrastructure for edge deployments of high-definition optical sensors and IoT devices that monitor traffic-related issues. These smart technologies will provide data to facilitate enhanced traffic management and mobility. As a first step in their “Connected Campus” initiative, UC Berkeley will leverage vehicle counting and classification to make informed decisions and develop specific solutions.
“At Berkeley, we are always trying to stay on top of emerging trends in parking and transportation, and by incorporating smart technologies, our campus can serve as a test bed for new technologies that can be put into operation immediately,” said Seamus Wilmot, Director of Parking and Transportation, UC Berkeley. “Our partnership with NTT and Dell Technologies makes us more digitally-enabled and provides a better understanding for alleviating the root causes of traffic issues. These technologies will help us solve how to manage the curb space at an area that has been challenging for our students, faculty, staff and partners.”
As part of the pilot, NTT and Dell Technologies will implement smart IoT, safety and security innovations that support UC Berkeley’s Parking and Transportation Department, such as real-time alerts and traffic statistics that improve predictions and outcomes. With quantifiable data, UC Berkeley can curb congestion caused by events, ride share traffic, delivery vehicles and transit operations.
The pilot program is designed to provide automated deployment and operation of necessary information and communications technology (ICT) resources from devices and networks to the cloud. The solution will ensure UC Berkeley can focus on improving traffic conditions through analysis and process more efficiently without worrying about ICT deployment and optimization issues.
“This traffic management pilot program begins UC Berkeley’s transformation to a Connected Campus,” said Akira Shimada, Senior Executive Vice President, NTT. “Connected Campuses of the future will offer endless possibilities—for safety, crowd control, traffic and facilities management. UC Berkeley is just getting started, but as a world renowned forward-thinking academic and research University, they see the potential to improve the campus experience and operations using data and smart technologies.”
NTT, along with its operating companies, will deploy its Accelerate Smart solution, which is a secure, distributed network as a platform solution built on NTT’s innovative Cognitive Foundation™ architecture. It enables remote creation, management and operation of information and communications technology resources, from devices and networks to the cloud. It also incorporates hyperconverged infrastructure and IoT gateways from Dell Technologies, as well as virtualization software hosting predictive analytics applications from VMware.
“When we leverage longstanding relationships with great partners like NTT, our joint customers can transform the way they do business,” said Denise Millard, Senior Vice President, Global Alliances, Dell Technologies. “Together we are able to provide customers like UC Berkeley with new tools to leverage data in meaningful ways and make decisions faster to ultimately improve the experience of those on campus.”
Following the initial pilot, UC Berkeley, NTT and Dell Technologies plan to evaluate viability to extend the pilot and potentially add additional locations and use cases on campus. To learn more about the NTT accelerating smart solutions, visit NTT DATA’s website and watch the Accelerate Smart case study with the city of Las Vegas on YouTube.
About NTT
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005333/en/
Contact information
Media Contact
Drew Wilson, NTT DATA Services
drew.wilson@nttdata.com
469.486.8653
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
